{"schema_version":"secwatch.filing_event.v1","accession":"0001477932-23-002688","form_type":"8-K","ticker":"COSM","cik":"0001474167","company_name":"Cosmos Health Inc.","filed_at":"2023-04-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.972808+00:00","generated_at":"2026-06-17T00:40:11.405060+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Cosmos Health FY2022 revenue down 10.5% to $50.3M; positive adjusted EBITDA, debt reduced 76%","bullets":["Revenue $50.3M vs $56.2M; constant-currency increase of $0.4M; net loss $13.8M vs $7.96M.","Adjusted EBITDA positive $0.5M (down from $3.3M in FY2021); going-concern doubt resolved.","Cash & securities $21M (vs $0.3M); long-term debt cut to $5.1M from $21.4M.","Raised $56.5M via equity/warrants; acquiring Cana Laboratories and ZipDoctor.","R&D partnership with Cloudpharm for obesity/diabetes; launched Mediterranation supplements."],"urls":{"canonical":"https://secwatch.observer/filing/0001477932-23-002688","json":"https://secwatch.observer/filing/0001477932-23-002688.json","markdown":"https://secwatch.observer/filing/0001477932-23-002688.md","text":"https://secwatch.observer/filing/0001477932-23-002688.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1474167/000147793223002688/0001477932-23-002688-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1474167/000147793223002688/cosm_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T00:40:11.405060+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1280079e079c23a274d3b4e07aed6472f4ff07c9","claim":"Cosmos Health Inc. reported fiscal year ended December 31, 2022 results: revenue $50.3 million, net income $(13,830,371).","evidence_excerpt":"devices, today provided a business update and reported financial results for the fiscal year ended December 31, 2022. Fiscal Year 2022 Financial Highlights · Revenues were $50.3 million versus $56.2 million in FY2021 with the decline being largely due to the high variation in FX differences between EUR and GBP to USD. When considered on a constant currency","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1474167/000147793223002688/0001477932-23-002688-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fiscal year ended December 31, 2022"},{"label":"Revenue","value":"$50.3 million"},{"label":"Net income","value":"$(13,830,371)"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}